Imaging features of toxicities associated with immune checkpoint inhibitors
| dc.contributor.author | Gosangi, Babina | |
| dc.contributor.author | McIntosh, Lacey | |
| dc.contributor.author | Keraliya, Abhishek | |
| dc.contributor.author | Irugu, David Victor Kumar | |
| dc.contributor.author | Baheti, Akshay | |
| dc.contributor.author | Khandelwal, Ashish | |
| dc.contributor.author | Thomas, Richard | |
| dc.contributor.author | Braschi-Amirfarzan, Marta | |
| dc.date.accessioned | 2022-11-21T15:24:15Z | |
| dc.date.available | 2022-11-21T15:24:15Z | |
| dc.date.issued | 2022-08-08 | |
| dc.identifier.citation | Gosangi B, McIntosh L, Keraliya A, Irugu DVK, Baheti A, Khandelwal A, Thomas R, Braschi-Amirfarzan M. Imaging features of toxicities associated with immune checkpoint inhibitors. Eur J Radiol Open. 2022 Aug 8;9:100434. doi: 10.1016/j.ejro.2022.100434. PMID: 35967881; PMCID: PMC9372737. | en_US |
| dc.identifier.issn | 2352-0477 | |
| dc.identifier.doi | 10.1016/j.ejro.2022.100434 | en_US |
| dc.identifier.pmid | 35967881 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/51263 | |
| dc.description.abstract | The past decade has witnessed a change in landscape of cancer management with the advent of precision oncology. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and have played an important role in improving patient survival. While the patients are living longer, treatment with ICIs are sometimes associated with adverse effects, some of which could be fatal. Radiologists can play a crucial role by early identification of some of these adverse effects during restaging scans. Our paper focuses on the imaging features of commonly occurring ICI toxicities based on organ system. | en_US |
| dc.language.iso | en | en_US |
| dc.relation.ispartof | European Journal of Radiology Open | en_US |
| dc.relation.url | https://doi.org/10.1016/j.ejro.2022.100434 | en_US |
| dc.rights | © 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | en_US |
| dc.rights | Attribution 4.0 International | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject | AIP, acute interstitial pneumonitis | en_US |
| dc.subject | ARDS, acute respiratory distress syndrome | en_US |
| dc.subject | CTCAE, Common Terminology Criteria for Adverse Events | en_US |
| dc.subject | CTLA-4 inhibitor, Cytotoxic T-lymphocyte antigen- 4 inhibitor | en_US |
| dc.subject | Colitis | en_US |
| dc.subject | FDA, Food and Drug Administration | en_US |
| dc.subject | Hepatitis | en_US |
| dc.subject | ICI, Immune check point inhibitor | en_US |
| dc.subject | Immune check point inhibitors toxicity | en_US |
| dc.subject | LGE, late Gadolinium enhancement | en_US |
| dc.subject | NSCLC, non-small cell lung cancer | en_US |
| dc.subject | NSIP, non-specific interstitial pneumonia | en_US |
| dc.subject | OP, organizing pneumonia | en_US |
| dc.subject | PD-1 inhibitor, programmed cell death-1 inhibitor | en_US |
| dc.subject | PD-L1 inhibitor, programmed cell death ligand-1 inhibitor | en_US |
| dc.subject | PFS, progression free survival | en_US |
| dc.subject | Pancreatitis | en_US |
| dc.subject | Pneumonitis | en_US |
| dc.subject | RRP, radiation recall pneumonitis | en_US |
| dc.subject | irAE, immune-related adverse event | en_US |
| dc.title | Imaging features of toxicities associated with immune checkpoint inhibitors | en_US |
| dc.type | Journal Article | en_US |
| dc.source.journaltitle | European journal of radiology open | |
| dc.source.volume | 9 | |
| dc.source.beginpage | 100434 | |
| dc.source.endpage | ||
| dc.source.country | England | |
| dc.identifier.journal | European journal of radiology open | |
| refterms.dateFOA | 2022-11-21T15:24:15Z | |
| dc.contributor.department | Radiology | en_US |
Files in this item
Name:
Publisher version
This item appears in the following Collection(s)
-
Radiology Publications [1100]
Except where otherwise noted, this item's license is described as © 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Related items
Showing items related by title, author, creator and subject.
-
Risk of COVID-19 in Dermatologic Patients on Long-term Immunomodulatory TherapyAs the COVID-19 pandemic has rapidly spread around the globe, concern has been raised regarding susceptibility of patients on immunomodulatory therapies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. While general guidance has been put forth, data regarding infection rate and outcomes in immunosuppressed patients is still rare.1 Recent articles, including the work by Gisondi, et al, suggest that outcomes of patients on systemic immunomodulatory therapies infected with SARS-CoV-2 are similar to the general population.2 These findings may relate to the aberrant cytokine and inflammatory responses in severe COVID-19, which may be treated or partially blunted by cytokine-targeted therapy.3 Given the substantial outbreak of COVID-19 in our community, we tested whether, in addition to similar outcomes, patients on systemic immunomodulatory therapy had similar infection rates compared to the general population.
-
Hippocampal c-Jun-N-terminal kinases serve as negative regulators of associative learningIn the adult mouse, signaling through c-Jun N-terminal kinases (JNKs) links exposure to acute stress to various physiological responses. Inflammatory cytokines, brain injury and ischemic insult, or exposure to psychological acute stressors induce activation of hippocampal JNKs. Here we report that exposure to acute stress caused activation of JNKs in the hippocampal CA1 and CA3 subfields, and impaired contextual fear conditioning. Conversely, intrahippocampal injection of JNKs inhibitors sp600125 (30 mum) or D-JNKI1 (8 mum) reduced activity of hippocampal JNKs and rescued stress-induced deficits in contextual fear. In addition, intrahippocampal administration of anisomycin (100 mug/mul), a potent JNKs activator, mimicked memory-impairing effects of stress on contextual fear. This anisomycin-induced amnesia was abolished after cotreatment with JNKs selective inhibitor sp600125 without affecting anisomycin's ability to effectively inhibit protein synthesis as measured by c-Fos immunoreactivity. We also demonstrated milder and transient activation of the JNKs pathway in the CA1 subfield of the hippocampus during contextual fear conditioning and an enhancement of contextual fear after pharmacological inhibition of JNKs under baseline conditions. Finally, using combined biochemical and transgenic approaches with mutant mice lacking different members of the JNK family (Jnk1, Jnk2, and Jnk3), we provided evidence that JNK2 and JNK3 are critically involved in stress-induced deficit of contextual fear, while JNK1 mainly regulates baseline learning in this behavioral task. Together, these results support the possibility that hippocampal JNKs serve as a critical molecular regulator in the formation of contextual fear.
-
Acute ischemic coronary artery disease and ischemic stroke: similarities and differencesAlthough acute myocardial infarction (MI) and acute ischemic stroke share similarities, physicians need to recognize important differences in pathophysiology and how these differences affect acute treatment and prevention to provide optimal patient care. Potential causes of acute ischemic stroke are substantially more heterogeneous than for acute MI, and available acute therapies are substantially more limited. In acute ischemic stroke patients, diagnostic evaluation is paramount in determining eligibility for treatment with the only approved therapy, which must be administered within 3 hours after stroke onset. For patients having acute MI, reperfusion therapy by percutaneous intervention or thrombolytic drug therapy is well established. Because atherosclerosis is a common pathway to acute MI and acute ischemic stroke, modifying associated known risk factors is required for primary and secondary prevention of both conditions. Pharmacologic therapies recommended for secondary prevention include beta-blockers and angiotensin-converting enzyme inhibitors for MI, oral anticoagulants for stroke, and statins and antiplatelet agents for both conditions. Aspirin is recommended for preventing recurrence of both MI and stroke; agents inhibiting the adenosine diphosphate pathway of platelet activation, such as ticlopidine and clopidogrel, are also beneficial. Recent studies suggest the benefits associated with adding aspirin to clopidogrel do not outweigh the significant increase in bleeding risk. The synergistic effects of aspirin plus extended-release dipyridamole make this combination twice as effective than aspirin alone in secondary prevention of ischemic stroke. An ongoing study is directly comparing the combination of aspirin plus extended-release dipyridamole with clopidogrel for the prevention of recurrent stroke.
